Sample size calculation in medical studies.
Mohamad Amin Pourhoseingholi, Mohsen Vahedi, Mitra Rahimzadeh
https://pubmed.ncbi.nlm.nih.gov/24834239/Actively Recruiting
Led by Marco Schiuma · Updated on 2026-05-13
150
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are investigating the use of therapeutic drug monitoring TDM to optimize the dosage of linezolid, a key drug in the BPaLBPaL-M regimen, for patients with multidrug-resistant tuberculosis MDR-TB. This study addresses the challenge of balancing linezolids effectiveness with its serious side effects, such as neuropathy and myelosuppression, which occur in a significant number of patients. The goal is to improve treatment outcomes and reduce adverse events by personalizing linezolid dosing based on blood drug levels. Participants will be randomly assigned to one of two groups. One group will receive the standard linezolid dose of 600 mg with regular TDM monitoring but no dose adjustments unless national guidelines require it. The other group will have their linezolid dose personalized according to TDM results, adjusting the dose based on specific blood concentration thresholds to balance efficacy and safety. Blood samples will be collected frequently during the 6-month treatment, including weekly samples in the first month and monthly thereafter, with additional samples taken if side effects arise. Throughout the study, participants will undergo regular blood sampling to monitor linezolid levels and side effects. Researchers will assess the rate of linezolid-related side effects, treatment success, and trends in drug levels throughout therapy. The total participation time is six months, during which clinical outcomes and the feasibility of dose personalization in low-resource settings will be evaluated.
CONDITIONS
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
M
Marco Schiuma
S
Souleymane Hassane Harouna
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Marco Schiuma
Lead Sponsor
ASST Fatebenefratelli Sacco
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive linezolid as part of the BPaL regimen with dosage personalization based on therapeutic drug monitoring (TDM) or standard dosing. Linezolid levels are monitored regularly to adjust dosage if needed according to TDM results.
Weekly visits for the first month and monthly visits for the following 5 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Mohamad Amin Pourhoseingholi, Mohsen Vahedi, Mitra Rahimzadeh
https://pubmed.ncbi.nlm.nih.gov/24834239/Francesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov...
https://pubmed.ncbi.nlm.nih.gov/36053506/Mahmoud Tareq Abdelwahab, Sean Wasserman, James C M Brust...
https://pubmed.ncbi.nlm.nih.gov/34543098/Jan-Willem C Alffenaar, Jos G W Kosterink, Richard van Altena...
https://pubmed.ncbi.nlm.nih.gov/20042919/Marco Schiuma
Lead Sponsor
ASST Fatebenefratelli Sacco
Collaborating Sponsor